Pharmacogenetics in Type 2 Diabetes Treatment.
- At: 2012 FIP Congress in Amsterdam (the Netherlands)
- Type: Poster
- By: SEMIZ, Sabina (University of Sarajevo, Faculty of Pharmacy, Sarajevo, Bosnia and Herzegovina)
- Co-author(s): Dujic, T. (University of Sarajevo, Sarajevo, Bosnia and Herzegovina)
Causevic-Ramosevac, A. (Bosnalijek, Sarajevo, Bosnia and Herzegovina)
Causevic, A. (University of Sarajevo, Sarajevo, Bosnia and Herzegovina)
Background: Type 2 diabetes (T2D) is a worldwide epidemic with considerable health and economic consequences. Diabetic patients are often treated with more than one oral antidiabetic drug (OAD), including metformin and sulfonylureas (SU). Genetic variations in drug-metabolizing enzymes (DME), drug-transporters (DT), and other specific drug targets.. The access to the whole abstract and the presentation file is available to FIP members and to congress participants of that specific congress.